Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2012

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Monday, August 1, 2011, to discuss the company’s financial results for the first quarter of fiscal 2012. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermes’ website at www.alkermes.com or may be accessed by dialing 1-888-424-8151 for domestic callers and 1-847-585-4422 for international callers. The conference call ID number is 6037988.

A replay of the conference call will be available from 7:30 p.m. ET on Monday, August 1, 2011, through 5:00 p.m. ET on Monday, August 8, 2011, and may be accessed by visiting Alkermes’ website or by dialing 1-888-843-7419 for domestic callers and 1-630-652-3042 for international callers. The replay access code is 6037988.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol and opioid dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

VIVITROL® is a trademark of Alkermes, Inc. RISPERDAL® CONSTA® is a trademark of Janssen-Cilag group of companies.



CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.